TFC Therapeutics is a biotechnology company developing novel biologics to target and eliminate key drivers of cancer. The Company's emerging technology platform is focused on targeting and eliminating Tumor Macrophage Hybrid (TMH) cells. TMH cells are implicated in metastasis, treatment resistance, and relapse. TFC was founded by scientists and executives with deep cancer biology expertise and a commitment to delivering benefit to patients based on rigorous pursuit of novel approaches to cancer therapy. TFC is headquartered in New York, NY and secured initial funding in August 2023.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.